TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs

21 hours ago 3

Maham Fatima

Wed, December 31, 2025 astatine 10:13 AM CST 2 min read

Orchestra BioMed Holdings Inc. (NASDAQ:OBIO) is 1 of the best biotech penny stocks to bargain according to analysts. On December 10, TD Cowen expert Joshua Jennings initiated sum of Orchestra BioMed with a Buy standing and $15 terms target. TD Cowen believes that Orchestra BioMed is astatine the starring borderline of cardiovascular instrumentality innovation. Its royalty-based exemplary is anchored by 2 cardinal programs: AVIM for hypertension and Virtue SAB for atherosclerotic disease, some of which people monolithic marketplace gaps. With blue-chip partners and high-margin potential, the institution is approaching captious information and commercialization milestones that could beryllium transformative.

The institution is presently advancing 2 high-impact pivotal programs. Enrollment officially initiated for the Virtue Trial arsenic of Q3 2025, which is simply a US registrational survey comparing Virtue SAB head-to-head against the commercially disposable AGENT paclitaxel-coated balloon for treating coronary in-stent restenosis. Orchestra BioMed Holdings Inc. (NASDAQ:OBIO) remains successful afloat operational power of this trial, with enrollment completion targeted for mid-2027. Simultaneously, the institution is progressing its BACKBEAT planetary pivotal survey for Atrioventricular Interval Modulation/AVIM Therapy. Recent FDA-approved protocol enhancements person expanded the enrollment criteria for BACKBEAT, expanding the eligible diligent excavation much than 24-fold, with enrollment completion expected successful mid-2026.

TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential successful Lead Cardiovascular Programs

Orchestra BioMed Holdings Inc. (NASDAQ:OBIO precocious expanded its concern with Medtronic, establishing a improvement pathway for AVIM Therapy-enabled leadless pacemakers. While Terumo holds a ROFR for definite transactions, Orchestra BioMed retains each improvement and organisation rights for Virtue SAB crossed each indications.

Orchestra BioMed Holdings Inc. (NASDAQ:OBIO) operates arsenic a biomedical institution successful the US. It collaborates with Medtronic for the improvement of AVIM therapy for the attraction of HTN successful pacemaker-indicated patients, and with Terumo Corporation and Terumo Medical Corporation for processing and commercializing Virtue SAB for the attraction of coronary and peripheral artery disease.

While we admit the imaginable of OBIO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.